Large Vessel Vasculitis
Özet
There is an elevated risk of cardiovascular disease (CVD) and mortality, particularly in large vessel vasculitides (LVV) such as Takayasu arteritis and giant cell arteritis. Cardiac manifestations associated with LVV may include hypertension, pathological changes in the pulmonary or coronary arteries, myocardial infiltration, and aortic regurgitation. Furthermore, the association between chronic inflammation and accelerated atherosclerosis is well established. Endothelial dysfunction, driven by inflammatory cytokines and oxidative stress, contributes to the development of early atherosclerosis.
In young patients presenting with unexplained acute coronary syndrome or congestive heart failure, coronary vasculitis should be included in the differential diagnosis. Coronary vasculitis can manifest as narrowing, occlusion, aneurysm, or rupture of the coronary vessels. In addition to coronary artery involvement, it may lead to clinical conditions such as valve disease, pericarditis, and myocarditis. Early diagnosis, prompt suppression of vascular inflammation, and prevention of further damage are crucial for improving prognosis. Additionally, encouraging smoking cessation, adopting a healthy diet, and engaging in low-intensity exercise are beneficial.
Özellikle Takayasu arteriti ve dev hücreli arterit gibi büyük damar vaskülitlerinde (LVV) kardiyovasküler hastalık ve mortalite riski yüksektir. LVV ile ilişkili kardiyak bulgular arasında hipertansiyon, pulmoner veya koroner arterlerde patolojik değişiklikler, miyokardiyal infiltrasyon ve aort yetmezliği yer alabilir. Ayrıca, kronik inflamasyon ile akselere ateroskleroz arasındaki bağlantı iyi bilinmektedir. İnflamatuvar sitokinler ve oksidatif stres tarafından indüklenen endotel disfonksiyonu, erken ateroskleroz gelişimine katkıda bulunur.
Açıklanamayan akut koroner sendrom veya konjestif kalp yetmezliği ile başvuran genç hastalarda, koroner vaskülit ayırıcı tanıda düşünülmelidir. Koroner vaskülit, koroner damarların daralmasına, tıkanmasına, anevrizma gelişimine veya rüptürüne neden olabilir. Koroner arter tutulumuna ek olarak, kapak hastalığı, perikardit ve miyokardit gibi klinik tablolar da görülebilir. Erken tanı, vasküler inflamasyonun ivedilikle baskılanması ve daha fazla hasarın önlenmesi prognozu iyileştirmek için çok önemlidir. Ayrıca, bu hastalarda sigarayı bırakmayı teşvik etmek, sağlıklı bir diyet benimsemek ve düşük yoğunluklu egzersiz yapmak faydalı olabilir.
Referanslar
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43.
Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology. 2009;48(1):11-22.
Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford, England). 2014;53(5):793-801.
Alibaz-Oner F, Aydin SZ, Direskeneli H. Advances in the diagnosis, assessment and outcome of Takayasu's arteritis. Clin Rheumatol. 2013;32(5):541-6.
Soto ME, Espinola-Zavaleta N, Ramirez-Quito O, Reyes PA. Echocardiographic follow-up of patients with Takayasu's arteritis: five-year survival. Echocardiography (Mount Kisco, NY). 2006;23(5):353-60.
Miloslavsky E, Unizony S. The heart in vasculitis. Rheumatic diseases clinics of North America. 2014;40(1):11-26.
Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu's arteritis. Autoimmun Rev. 2007;6(8):566-71.
Li J, Li H, Sun F, Chen Z, Yang Y, Zhao J, et al. Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis. J Rheumatol. 2017;44(12):1867-74.
Alibaz-Oner F, Koster MJ, Unal AU, Yildirim HG, Çikikçi C, Schmidt J, et al. Assessment of the frequency of cardiovascular risk factors in patients with Takayasu's arteritis. Rheumatology (Oxford, England). 2017;56(11):1939-44.
Zhang Y, Yang K, Meng X, Tian T, Fan P, Zhang H, et al. Cardiac Valve Involvement in Takayasu Arteritis Is Common: A Retrospective Study of 1,069 Patients Over 25 Years. The American journal of the medical sciences. 2018;356(4):357-64.
Lee GY, Jang SY, Ko SM, Kim EK, Lee SH, Han H, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. International journal of cardiology. 2012;159(1):14-20.
Li J, Zhu M, Li M, Zheng W, Zhao J, Tian X, et al. Cause of death in Chinese Takayasu arteritis patients. Medicine (Baltimore). 2016;95(27):e4069.
Matsuura K, Ogino H, Kobayashi J, Ishibashi-Ueda H, Matsuda H, Minatoya K, et al. Surgical treatment of aortic regurgitation due to Takayasu arteritis: long-term morbidity and mortality. Circulation. 2005;112(24):3707-12.
Versini M, Tiosano S, Sharif K, Mahroum N, Watad A, Comaneshter D, et al. Association between Takayasu arteritis and ischemic heart disease: a cohort study. Mediterranean journal of rheumatology. 2019;30(3):171-6.
Kim H, Barra L. Ischemic complications in Takayasu's arteritis: A meta-analysis. Seminars in arthritis and rheumatism. 2018;47(6):900-6.
Kang EJ, Kim SM, Choe YH, Lee GY, Lee KN, Kim DK. Takayasu arteritis: assessment of coronary arterial abnormalities with 128-section dual-source CT angiography of the coronary arteries and aorta. Radiology. 2014;270(1):74-81.
Matsubara O, Kuwata T, Nemoto T, Kasuga T, Numano F. Coronary artery lesions in Takayasu arteritis: pathological considerations. Heart and vessels Supplement. 1992;7:26-31.
Lei C, Huang Y, Yuan S, Chen W, Liu H, Yang M, et al. Takayasu Arteritis With Coronary Artery Involvement: Differences Between Pediatric and Adult Patients. The Canadian journal of cardiology. 2020;36(4):535-42.
Banerjee S, Bagheri M, Sandfort V, Ahlman MA, Malayeri AA, Bluemke DA, et al. Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia. Seminars in arthritis and rheumatism. 2019;48(6):1068-73.
Seyahi E, Ugurlu S, Cumali R, Balci H, Seyahi N, Yurdakul S, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis. 2006;65(9):1202-7.
Endo M, Tomizawa Y, Nishida H, Aomi S, Nakazawa M, Tsurumi Y, et al. Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arteritis. The Journal of thoracic and cardiovascular surgery. 2003;125(3):570-7.
Comarmond C, Cluzel P, Toledano D, Costedoat-Chalumeau N, Isnard R, Gaudric J, et al. Findings of cardiac magnetic resonance imaging in asymptomatic myocardial ischemic disease in Takayasu arteritis. The American journal of cardiology. 2014;113(5):881-7.
Pan W, LI M, XU D, Hou Y, Zeng X, Zhang F. Myocardial involvement in patients with Takayasu arteritis. Chinese Journal of Rheumatology. 2015:335-8.
Wang X, Dang A, Chen B, Lv N, Liu Q. Takayasu arteritis-associated pulmonary hypertension. J Rheumatol. 2015;42(3):495-503.
Sari A, Sener YZ, Firat E, Armagan B, Erden A, Oksul M, et al. Pulmonary hypertension in Takayasu arteritis. International Journal of Rheumatic Diseases. 2018;21(8):1634-9.
Toledano K, Guralnik L, Lorber A, Ofer A, Yigla M, Rozin A, et al. Pulmonary arteries involvement in Takayasu's arteritis: two cases and literature review. Seminars in arthritis and rheumatism. 2011;41(3):461-70.
Egebjerg K, Baslund B, Obel N, Faurschou M. Mortality and cardiovascular morbidity among patients diagnosed with Takayasu's arteritis: a Danish nationwide cohort study. Clin Exp Rheumatol. 2020;38 Suppl 124(2):91-4.
Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmunity reviews. 2012;11(6-7):A544-A54.
Mahr A, Aouba A, Richebé P, Gonzalez-Chiappe S. Epidemiology and natural history of giant cell arteritis. La Revue de medecine interne. 2017;38(10):663-9.
Gonzalez-Gay MA, Rubiera G, Piñeiro A, Garcia-Porrua C, Pego-Reigosa R, Gonzalez-Juanatey C, et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. The Journal of Rheumatology. 2005;32(3):502-6.
Le Page L, Duhaut P, Seydoux D, Bosshard S, Ecochard R, Abbas F, et al. Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG). La Revue de medecine interne. 2005;27(2):98-105.
Kebed DT, Bois JP, Connolly HM, Scott CG, Bowen JM, Warrington KJ, et al. Spectrum of aortic disease in the giant cell arteritis population. The American journal of cardiology. 2018;121(4):501-8.
Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large‐artery complication (aortic aneurysm, aortic dissection, and/or large‐artery stenosis) in patients with giant cell arteritis: a population‐based study over 50 years. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2003;48(12):3522-31.
Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large‐artery complication (aortic aneurysm, aortic dissection, and/or large‐artery stenosis) in patients with giant cell arteritis: a population‐based study over 50 years. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2003;48(12):3532-7.
Fayyaz B, Rehman HJ. The spectrum of pericardial involvement in giant cell arteritis and polymyalgia rheumatica: a systematic review of literature. JCR: Journal of Clinical Rheumatology. 2021;27(1):5-10.
Ray J, Mamdani M, Geerts W. Giant cell arteritis and cardiovascular disease in older adults. Heart (British Cardiac Society). 2005;91(3):324-8.
Tomasson G, Peloquin C, Mohammad A, Love TJ, Zhang Y, Choi HK, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Annals of internal medicine. 2014;160(2):73-80.
Amiri N, De Vera M, Choi HK, Sayre EC, Avina-Zubieta JA. Increased risk of cardiovascular disease in giant cell arteritis: a general population–based study. Rheumatology. 2016;55(1):33-40.
Ungprasert P, Koster MJ, Warrington KJ, editors. Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. Seminars in arthritis and rheumatism; 2015: Elsevier.
Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. Which patients with giant cell arteritis will develop cardiovascular or cerebrovascular disease? A clinical practice research datalink study. The Journal of rheumatology. 2016;43(6):1085-92.
Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. The Canadian journal of cardiology. 2000;16(4):505-11.
Monti S, Robson J, Klersy C, Kraven A, Montecucco C, Watts R, et al. Early development of new cardiovascular risk factors in the systemic vasculitides. Clin Exp Rheumatol. 2019.
Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis & Rheumatism. 2002;46(2):457-66.
Kagami S-i, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. International immunology. 2009;21(6):679-89.
Schmidt J, Kermani TA, Muratore F, Crowson CS, Matteson EL, Warrington KJ. Statin use in giant cell arteritis: a retrospective study. The Journal of rheumatology. 2013;40(6):910-5.
Pugnet G, Sailler L, Fournier J-P, Bourrel R, Montastruc J-L, Lapeyre-Mestre M. Predictors of cardiovascular hospitalization in giant cell arteritis: effect of statin exposure. A French population-based study. The Journal of Rheumatology. 2016;43(12):2162-70.
Grasland A, Pouchot J, Hachulla E, Blétry O, Papo T, Vinceneux P. Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology. 2004;43(8):1007-15.
Beltagy A, Eshak N, Abdelnabi MH, Almaghraby A, Magdy S, Shehata H. Aortic valve perforation in the setting of Cogan's syndrome. Echocardiography (Mount Kisco, NY). 2019;36(8):1590-3.
Gelfand ML, Kantor T, Gorstein F. Cogan's syndrome with cardiovascular involvement: aortic insufficiency. Bulletin of the New York Academy of Medicine. 1972;48(4):647.
